Says something that no main stream news channel #skynews #bbcnews has picked up who wasn't mentioned as making America..... slavery and the forced migration of people from the Africa not acknowledge by Rubio @bbcnewsnight.bsky.social @channel4news.bsky.social
No joke: I got angry hate mail today for writing an obituary of a Black woman scientist—because the person felt she did didn’t deserve the recognition.
Which just makes me want to share it again: www.nature.com/articles/d41...
I've liked this, but truly 5k every day....I'll think of you whilst chilling with a coffee! Jx
Dear Gods of all that is stupid...
IT'S REAL.
Odd that your bio doesn't say which party you're an MP for. I wondered if it was Reform, but maybe that's your intention. Good to remove illegal migrants, and please fine those businesses creating a pull for them to come, but 'cleaning up' terrible language.
Trainees or doctors in postgraduate training?
Three marble statues all holding their hands up to their faces
The trouble is, once I started imagining they were taking selfies I couldn’t unsee it
Had this yesterday. The overground trains didn't have crew or drivers. It was a like a lottery if I would get home or spend £££ on a taxi.
BTOG is delighted to present an on-site professional childcare service at #BTOG25, acknowledging the requirements of our conference delegates who may be accompanied by their young children.
Details on the website
www.btog.org/23rd-btog-an...
Congratulations!
NEW NICE APPROVAL published today. NICE has appraised durvalumab within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy ... (continued) #LCSM #lungcancer
Final OS results from RELAY (1L erlotinib +/- ramucirumab in #EGFR NSCLC) now @jtoonline.bsky.social. Regimen FDA approved based on PFS benefit. After 45m f/u, no OS difference (51m vs 46m, HR 0.98). Over 80% received 2L therapy (osimertinib use similar in both arms).
www.jto.org/article/S155...
Finally!
Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
Real world outcomes with dabrafenib + trametinib in #BRAF V600E NSCLC in "Lung Cancer" (IFCT-2004 BLaDE, n=163). First-line: RR 83%, PFS 18m, OS 24m. Later line: RR 74%, PFS 10m, OS 20m. D/C for toxicity ~10%. Curious about IO outcomes by smoking history.
www.lungcancerjournal.info/article/S016...
Skyscraper (phase 3 trial of tira plus atezo in PD-L1 high advanced lung cancer) ultimately negative. The rollercoaster is finally back at base, disappointing news and doesn’t bode well for TIGIT as a target. #lcsm
www.gene.com/media/press-...
Press release: phase III SKYSCRAPER-01 study negative for OS at final analysis. Adding anti-TIGIT tiragolumab to first line atezolizumab in advanced PDL1 high NSCLC did not improve PFS or OS. Now to dissect what happened between phase II and III.
www.gene.com/media/press-...
Presented today at #RCPathGenomics about NHSE cfDNA pilot. Token oncologist in the room. Not sure what @bsky.app version of a tweetorial is. Issues addressed within the pilot can be found at www.roche-images.co.uk/Genomics_Lun...
Don’t be had… Which report in 2021 found 98pc of goods on sale Black Friday were same price at other times of the year. If you genuinely need something make sure you KNOW it’s a good deal and avoid “
Browsing”.. if you don’t know you need you probably don’t!!
Final survival results from phase II study of lorlatinib in #ALK NSCLC @jtoonline.bsky.social. In treatment naive (n=30), 5y OS 76%. Post 2nd gen ALK TKI ± chemo (n=28), 5y OS 45%, median OS 37.4m. Post ≥2 ALK TKIs ± chemo (n=111), 5y OS 23%, median OS 19.2m. #LCSM
www.jto.org/article/S155...
Dr. Liza Villaruz at #MaTOS24 discusses #NTRK and NSCLC. Three approved agents: larotrectinib, entrectinib, and now repotrectinib. Effective but note on target toxicities including dizziness, paresthesias, weight gain, pain withdrawal - on target toxicities to watch for. #LCSM #OncSky
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
Because some damn fool asked, here's a thread about Baxter.
This was taken on the day I brought home Baxter and threw away all hope of an easy life.
Look at him. Absolutely irresistible.
And that's how they get you, the utter bastards
@prof-ali-g.bsky.social and @tnewsomdavis.bsky.social
Me and @drmaryobr.bsky.social
Octavia Butler being a time traveler or seer, will forever be a hill I'm willing to die on, because there's just no way. Parable of The Sower was published in 1993. Look at this date. #BlackBookSky #BookSky
www.lungcancerjournal.info/article/S016...
Welcome to #oncsky @dralexiusjohn.bsky.social
Celebrate with our paper evaluating the metabolic toxicities of Lorlatinib published in Lungcancer this week
